Search

everythinglearnresearchcommunity

for

Search:↓

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.

User Basic_Football999 discusses concerns about negative dutasteride experiences. Replies suggest dutasteride is effective, but some users may have issues with dosing frequency or genetic factors affecting results.

Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

The user has been using finasteride for over two years with mixed results and is considering starting dutasteride and oral minoxidil, though both are hard to obtain. They are also contemplating a hair transplant in the future due to diffuse thinning.

A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.

The user is seeking advice on treating male pattern baldness (MPB) while dealing with seborrheic dermatitis, specifically asking about the use of finasteride (Fin) and minoxidil (Min). They are concerned about side effects and are looking for recommendations to improve overall hair thickness, especially on the crown.

Finasteride is more accepted than hair systems because it is less visible and maintains natural hair. Treatments like minoxidil and finasteride are commonly used for hair loss, but opinions on hair systems vary.

Considering a switch from finasteride to dutasteride for hair loss treatment, and the use of minoxidil as a last resort due to its effects on hair texture.

The conversation is about updates on hair loss treatments Breezula or PTD-DBM. No new information was provided.

Finasteride has been effective for maintaining hair density, but due to a slight dip in temple hair, the user switched to dutasteride as an additional measure. Users discuss varying experiences with side effects from finasteride, dutasteride, and minoxidil, highlighting that reactions can differ significantly among individuals.

Hair loss discussion includes finasteride intolerance and questioning if Pyrilutamide is an alternative. Pyrilutamide not commercially available, but may be tolerable if approved since it's not a 5aR inhibitor.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

Minoxidil is applied beyond the crown, including the hairline and other areas, despite labels suggesting crown use only. Users report success with broader application, and some prefer oral minoxidil for convenience.

The user discusses their hair loss experience, exploring various hypotheses including thyroid levels, vitamin D, DHEA, nutritional deficiency, diabetes, seborrheic dermatitis, lack of nutrition to hair follicles, chronic inflammation, female pattern hair loss causes, cortisol, and prolactin levels. They are currently using finasteride, beta-sitosterol, and have tried topical dutasteride and microneedling therapy.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

The conversation discusses using B6 and Zinc to inhibit 5ar activity, similar to Fin and Dut. Minoxidil is mentioned as a supplementary treatment.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Breezula protects hair follicles from both testosterone and DHT, unlike finasteride, which only protects against DHT. This could potentially lead to significant hair regrowth, similar to results seen in transgender individuals using hormone blockers.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

The conversation discusses concerns about body dysmorphia related to hair loss, with some users expressing frustration over posts claiming treatments like finasteride and dutasteride are ineffective or harmful despite minimal hair loss. It emphasizes the importance of early treatment with medications like finasteride and minoxidil for those experiencing hair loss.

Finasteride and Dutasteride are under review in the EU due to concerns about side effects like depression, but they are unlikely to be banned. Access to these medications varies, with easier availability in the UK compared to some EU countries.

Topical Dutasteride is unavailable in Germany, and the user is seeking ways to import it. They are exploring online options for obtaining the treatment.

Hair loss treatments Finasteride and Dutasteride are discussed, with emphasis on their safety and effectiveness. Users share frustration about fear-mongering and side effect discussions, suggesting trust in scientific studies and FDA approval.

Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

The conversation is about someone seeking a doctor in the EU who prescribes spironolactone or bicalutamide for female pattern hair loss, as they are having difficulty finding treatment options beyond Minoxidil in Austria. They are asking for recommendations and are open to direct messages for assistance.